Novartis releases Afinitor breast cancer BOLERO-2 secondary endpoint data

Business Agency, March 20 (Upi) -- Novartis released secondary endpoint data for the anti-cancer drug Afinitor Breast Cancer Phase III BOLERO-2 at the 9th European Breast Cancer Conference (EBCC-9) on March 19BOLERO-2 study involved more than 700 patients at 195 sites worldwideIn the study, patients were randomly (2:1) subjected to Afinitor (10 mg/day) or placebo continuing therapy, while the patient was treated with exemestane (25 mg/day)The primary endpoint isdiseaseprogressionless survival (PFS), and the secondary endpoint seistar includes total survival (OS), total mitigation rate, adverse event incidence rate, prognosis of patient self-reported, and clinical benefit ratestudy data showed that the average total survival of the combined treatment group was 31 months, the average total survival of the esmetanyan single-drug treatment group was 26 months, the difference was 4.4 months (HR-0.89, p-0.1426), and did not reach the statistical significance thresholdThis is the longest total lifetime data ever obtained in a Phase III clinical trial conducted in a group of patients with HR-HER2-advanced breast cancer who have previously been treated with nonsteroidal aromatase inhibitors (NSAI)previously, the BOLERO-2 study of disease non-progressive survival (PFS) data, Afinitor and Isimetan combined treatment group for 7.8 months, is is a single drug treatment group of 3.2 months (HR -0.45, p 0.0001
).About Afinitor:Afinitor is the first and only mTOR inhibitor approved for HR-/HER2-breast cancer, and has been approved by more than 80 countries for hormone receptor-positive (exemestane) Treatment of HR plus) and human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (HR-type advanced breast cancer) is applicable to postmenopausal women who relapse or progressoon after receiving nonsteroidal aromatase inhibitor drug therapy and have no symptoms of visceral diseaseAfinitor is targeted at the PI3K/AKT/mTOR signaling pathway, which is in a hyperactive dysactive state in a variety oftumormTOR is a protein, is an important regulatory factor in cell division, vascular growth, and cell metabolismData have confirmed that blocking mTOR is an effective way to maximize the clinical benefits of existing advanced breast cancer therapiesHR-HER2-advanced breast cancer is the most common type of breast cancer, about 70% of invasive breast cancer at the time of diagnosis of HR plus